Similar articles

• Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry.

  Wolff D, Culakova E, Poniewierski MS, Lyman GH, Dale DC, Crawford J; Awareness of Neutropenia in Chemotherapy Study Group. Wolff D, et al. J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):24-5. J Support Oncol. 2005. PMID: 16355556 No abstract available.
• Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.

  Donohue R. Donohue R. Oncol Nurs Forum. 2006 Nov 3;33(2):347-52. doi: 10.1188/06.ONF.347-352. Oncol Nurs Forum. 2006. PMID: 16518450
• Managing hematologic toxicities in the oncology patient.

  Montoya L. Montoya L. J Infus Nurs. 2007 May-Jun;30(3):168-72. doi: 10.1097/01.NAN.0000270676.59180.c3. J Infus Nurs. 2007. PMID: 17505218 Review.
• Neutropenia: state of the knowledge part I.

  Nirenberg A, Bush AP, Davis A, Friese CR, Gillespie TW, Rice RD. Nirenberg A, et al. Oncol Nurs Forum. 2006 Nov 27;33(6):1193-201. doi: 10.1188/06.ONF.1193-1201. Oncol Nurs Forum. 2006. PMID: 17149402 Review.
• [Myelotoxicity due to chemotherapy in oncology practice].

  Geoffrois L. Geoffrois L. Rev Prat. 2006 Nov 30;56(18):2009-14. Rev Prat. 2006. PMID: 17274503 Review. French.